Difference between revisions of "Urothelial dysplasia"

Jump to navigation Jump to search
Line 80: Line 80:
! Ki-67
! Ki-67
! p53
! p53
! p63 ‡
|-
|-
| Benign (reactive)
| Benign (reactive)
Line 85: Line 86:
| -ve <=10% of cells (+/-rare basal cells)  
| -ve <=10% of cells (+/-rare basal cells)  
| -ve <20% of cells (+/-weak staining)  
| -ve <20% of cells (+/-weak staining)  
| -ve
|-
|-
| Urothelial dysplasia
| Urothelial dysplasia
Line 90: Line 92:
| +ve >10% of cells (~40% of cases)
| +ve >10% of cells (~40% of cases)
| +ve >=20% of cells (~70% of cases)
| +ve >=20% of cells (~70% of cases)
| -ve <ref name=pmid19690775>{{Cite journal  | last1 = Stepan | first1 = A. | last2 = Mărgăritescu | first2 = C. | last3 = Simionescu | first3 = C. | last4 = Ciurea | first4 = R. | title = E-cadherin and p63 immunoexpression in dysplastic lesions and urothelial carcinomas of the bladder. | journal = Rom J Morphol Embryol | volume = 50 | issue = 3 | pages = 461-5 | month =  | year = 2009 | doi =  | PMID = 19690775 }}</ref><ref name=OJP>{{Cite journal | last1 = Raheem| first1 = Sayad A.| last2 = Saied | first2 = Abdel N. | last3 = Al Shaer | first3 =  Rabee | last4 =  Mustafa | first4 = Osama | last5 = Ali | first5 = Ali H.  | title = The Role of CK20, p53 and p63 in Differentiation of Some Urothelial Lesions of Urinary Bladder, Immunohistochemical Study  | journal = [http://www.scirp.org/journal/ojpathology Open Journal of Pathology] | volume = | issue = 4| pages = 181-193 | month = | year = 2014 | doi = 10.4236/ojpathology.2014.44024 | PMID = | PMC = | url = }}</ref>
|-
|-
| [[Urothelial carcinoma in situ|Urothelial carcinoma in situ]] (UCIS)
| [[Urothelial carcinoma in situ|Urothelial carcinoma in situ]] (UCIS)
Line 95: Line 98:
| +ve >10% of cells (~95% of cases)
| +ve >10% of cells (~95% of cases)
| +ve >=20% of cells (~80% of cases)
| +ve >=20% of cells (~80% of cases)
| +ve <ref name=pmid19690775/><ref name=OJP/>
|}
|}


Morphology is considered the gold standard for UCIS versus urothelial dysplasia;{{fact}} however, there is a small literature on IHC for dysplasia versus UCIS that is published in lesser known journals and suggests:<ref name=pmid19690775>{{Cite journal  | last1 = Stepan | first1 = A. | last2 = Mărgăritescu | first2 = C. | last3 = Simionescu | first3 = C. | last4 = Ciurea | first4 = R. | title = E-cadherin and p63 immunoexpression in dysplastic lesions and urothelial carcinomas of the bladder. | journal = Rom J Morphol Embryol | volume = 50 | issue = 3 | pages = 461-5 | month =  | year = 2009 | doi =  | PMID = 19690775 }}</ref><ref>{{Cite journal | last1 = Raheem| first1 = Sayad A.| last2 = Saied | first2 = Abdel N. | last3 = Al Shaer | first3 =  Rabee | last4 =  Mustafa | first4 = Osama | last5 = Ali | first5 = Ali H.  | title = The Role of CK20, p53 and p63 in Differentiation of Some Urothelial Lesions of Urinary Bladder, Immunohistochemical Study  | journal = [http://www.scirp.org/journal/ojpathology Open Journal of Pathology] | volume = | issue = 4| pages = 181-193 | month = | year = 2014 | doi = 10.4236/ojpathology.2014.44024 | PMID = | PMC = | url = }}</ref>
Note:
*p63 -ve at surface in dysplasia.
*‡ Morphology is considered the gold standard for UCIS versus urothelial dysplasia;{{fact}} however, there is a small literature on [[p63]] for dysplasia versus UCIS that is published in lesser known journals.
**p63 +ve at surface in UCIS


==Sign out==
==Sign out==
48,830

edits

Navigation menu